FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044408369> ?p ?o ?g. }

• W2044408369 endingPage "2399" @default.
• W2044408369 startingPage "2393" @default.
• W2044408369 abstract "BACKGROUND The impact of sequential trimodality therapy on the pattern of first site disease failure in pathologic Stage IIIA (N2) nonsmall cell lung carcinoma (NSCLC) was analyzed. METHODS Seventy-four eligible patients with histologically documented Stage IIIA (N2) NSCLC underwent sequential trimodality therapy on Cancer and Leukemia Group B (CALGB) Protocol 8935. Treatment consisted of 2 cycles of induction cisplatin at 100 mg/m2 intravenously (i.v.) (Days 1 and 29) and vinblastine at 5 mg/m2 i.v. weekly for 5 weeks followed by surgery. Surgery included a thoracotomy with resection of the primary tumor and hilar lymph nodes and a mediastinal lymph node dissection. Patients with resected disease then received an additional 2 cycles of cisplatin at 100 mg/m2 i.v. and vinblastine at 5 mg/m2 i.v. biweekly for a total of 4 doses followed by consolidative thoracic irradiation. Patients with completely resected disease received 54 Gray (Gy) whereas those with incompletely resected disease received 59.4 Gy at 1.8 Gy/fraction (fx) once a day. Patients with unresectable disease underwent thoracic radiation therapy (TRT) treatments only to 59.4 Gy at 1.8 Gy/fx without any additional chemotherapy. Disease recurrence was determined by clinical, radiographic, or histologic criteria. Pattern of disease failure was identified by site of involvement at first recurrence as indicated by the CALGB Respiratory Follow-Up Form. RESULTS Sixty-three of the 74 patients completed the induction chemotherapy as planned. Forty-six of the 63 patients underwent resection of disease whereas the remaining 17 were unresectable. Thirty-three of the 46 resected patients completed the entire adjuvant postoperative chemoradiation treatment as planned. Ten of 17 patients with unresectable disease completed postsurgical TRT. At a median follow-up interval of 27 months (range, 4–43), the 3-year overall survival and failure-free survival were 23% and 18%, respectively, for all 74 eligible patients. Overall, disease failure has occurred in 52 (70%) of the 74 eligible patients: local only: 13 (25%); distant only: 16 (31%); and both local and distant: 23 (44%), (P = not significant [NS]). Ten patients progressed during induction chemotherapy: local only: six patients; and both local and distant failure: four patients. Twenty-eight of 46 resected patients recurred: local only: 1 (4%); both local and distant failure: 11 (39%); and distant only: 16 (57%); (P < 0.001). Disease progression occurred in 14 of 17 patients with unresectable disease: local only: 6; both local and distant sites: 8. Among the 52 total patients experiencing disease relapse, isolated or combined local failure occurred commonly among patients during induction chemotherapy (n = 10, [28%]), in those with unresectable disease (n = 14, [39%]), or in those with resected disease (n = 12, [33%]), (P = NS). However, isolated or combined distant failure was more likely to occur among patients with resected disease (n = 27, [69%]) than either during induction chemotherapy (n = 4, [10%]) or in those with unresected disease (n = 8, [21%]), (P < 0.05). Among patients who relapsed, brain metastases occurred in 13 of 52 (25%) patients overall and in 12 of 28 (43%) patients with resected disease. CONCLUSIONS Overall, disease failure was just as likely to occur in local, distant, or combined sites on CALGB Protocol 8935 using sequential trimodality therapy in the treatment of pathologic Stage IIIA (N2) NSCLC. Isolated or combined local failure occurred commonly during sequential tri-modality therapy whereas isolated or combined distant relapse was prevalent among patients with resected disease. In addition, isolated local failure was rare among patients with resected disease. The pattern of disease failure on CALGB Protocol 8935 reflects the biology of locoregional NSCLC as much as the therapeutic impact of trimodality therapy. Cancer 1996;77:2393-9." @default.
• W2044408369 created "2016-06-24" @default.
• W2044408369 creator A5011590188 @default.
• W2044408369 creator A5015338018 @default.
• W2044408369 creator A5045600892 @default.
• W2044408369 creator A5053870754 @default.
• W2044408369 creator A5057242210 @default.
• W2044408369 creator A5060675145 @default.
• W2044408369 creator A5063930778 @default.
• W2044408369 creator A5075108469 @default.
• W2044408369 creator A5079345600 @default.
• W2044408369 creator A5091848952 @default.
• W2044408369 date "1996-06-01" @default.
• W2044408369 modified "2023-10-18" @default.
• W2044408369 title "Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2): Analysis of Cancer and Leukemia Group B Protocol 8935" @default.
• W2044408369 cites W1950679458 @default.
• W2044408369 cites W1987914801 @default.
• W2044408369 cites W2019779587 @default.
• W2044408369 cites W2045900026 @default.
• W2044408369 cites W2049475989 @default.
• W2044408369 cites W2089514388 @default.
• W2044408369 cites W2104325484 @default.
• W2044408369 cites W2138310931 @default.
• W2044408369 cites W2155709777 @default.
• W2044408369 cites W2317448174 @default.
• W2044408369 cites W2400914614 @default.
• W2044408369 doi "https://doi.org/10.1002/(sici)1097-0142(19960601)77:11<2393::aid-cncr31>3.0.co;2-q" @default.
• W2044408369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8635112" @default.
• W2044408369 hasPublicationYear "1996" @default.
• W2044408369 type Work @default.
• W2044408369 sameAs 2044408369 @default.
• W2044408369 citedByCount "66" @default.
• W2044408369 countsByYear W20444083692012 @default.
• W2044408369 countsByYear W20444083692013 @default.
• W2044408369 countsByYear W20444083692015 @default.
• W2044408369 countsByYear W20444083692016 @default.
• W2044408369 countsByYear W20444083692017 @default.
• W2044408369 countsByYear W20444083692018 @default.
• W2044408369 countsByYear W20444083692021 @default.
• W2044408369 countsByYear W20444083692022 @default.
• W2044408369 crossrefType "journal-article" @default.
• W2044408369 hasAuthorship W2044408369A5011590188 @default.
• W2044408369 hasAuthorship W2044408369A5015338018 @default.
• W2044408369 hasAuthorship W2044408369A5045600892 @default.
• W2044408369 hasAuthorship W2044408369A5053870754 @default.
• W2044408369 hasAuthorship W2044408369A5057242210 @default.
• W2044408369 hasAuthorship W2044408369A5060675145 @default.
• W2044408369 hasAuthorship W2044408369A5063930778 @default.
• W2044408369 hasAuthorship W2044408369A5075108469 @default.
• W2044408369 hasAuthorship W2044408369A5079345600 @default.
• W2044408369 hasAuthorship W2044408369A5091848952 @default.
• W2044408369 hasBestOaLocation W20444083691 @default.
• W2044408369 hasConcept C121608353 @default.
• W2044408369 hasConcept C126322002 @default.
• W2044408369 hasConcept C141071460 @default.
• W2044408369 hasConcept C146357865 @default.
• W2044408369 hasConcept C151730666 @default.
• W2044408369 hasConcept C2776256026 @default.
• W2044408369 hasConcept C2776694085 @default.
• W2044408369 hasConcept C2777132456 @default.
• W2044408369 hasConcept C2777546739 @default.
• W2044408369 hasConcept C2778822529 @default.
• W2044408369 hasConcept C2779013556 @default.
• W2044408369 hasConcept C2780379385 @default.
• W2044408369 hasConcept C2780849966 @default.
• W2044408369 hasConcept C509974204 @default.
• W2044408369 hasConcept C71924100 @default.
• W2044408369 hasConcept C86803240 @default.
• W2044408369 hasConcept C90924648 @default.
• W2044408369 hasConceptScore W2044408369C121608353 @default.
• W2044408369 hasConceptScore W2044408369C126322002 @default.
• W2044408369 hasConceptScore W2044408369C141071460 @default.
• W2044408369 hasConceptScore W2044408369C146357865 @default.
• W2044408369 hasConceptScore W2044408369C151730666 @default.
• W2044408369 hasConceptScore W2044408369C2776256026 @default.
• W2044408369 hasConceptScore W2044408369C2776694085 @default.
• W2044408369 hasConceptScore W2044408369C2777132456 @default.
• W2044408369 hasConceptScore W2044408369C2777546739 @default.
• W2044408369 hasConceptScore W2044408369C2778822529 @default.
• W2044408369 hasConceptScore W2044408369C2779013556 @default.
• W2044408369 hasConceptScore W2044408369C2780379385 @default.
• W2044408369 hasConceptScore W2044408369C2780849966 @default.
• W2044408369 hasConceptScore W2044408369C509974204 @default.
• W2044408369 hasConceptScore W2044408369C71924100 @default.
• W2044408369 hasConceptScore W2044408369C86803240 @default.
• W2044408369 hasConceptScore W2044408369C90924648 @default.
• W2044408369 hasIssue "11" @default.
• W2044408369 hasLocation W20444083691 @default.
• W2044408369 hasLocation W20444083692 @default.
• W2044408369 hasOpenAccess W2044408369 @default.
• W2044408369 hasPrimaryLocation W20444083691 @default.
• W2044408369 hasRelatedWork W1519773982 @default.
• W2044408369 hasRelatedWork W1965964706 @default.
• W2044408369 hasRelatedWork W2098612596 @default.
• W2044408369 hasRelatedWork W2110805450 @default.
• W2044408369 hasRelatedWork W2369324096 @default.
• W2044408369 hasRelatedWork W2413365644 @default.
• W2044408369 hasRelatedWork W243427647 @default.

• next